EBOS Loses Bull Following Soft Annual Result -- Market Talk

Like
Comment
Favorite

EBOS Loses Bull Following Soft Annual Result -- Market Talk

Dow Jones08-28

0044 GMT - Pharmacy group Ebos's disappointing FY 2025 result costs it a bull. Forsyth Barr downgrades Ebos to neutral from outperform, and cuts its price target by 19% to NZ$37.25 after making material reductions to its earnings forecasts and projecting higher capex. Analyst Matt Montgomerie says the drivers of Ebos's softer-than-expected result and outlook commentary don't appear to be structural. Forsyth Barr still sees Ebos as positioned for medium-term growth. "But at 23x our revised 12-month forward EPS with a high single-digit three-year forward EPS compound annual growth rate, we don't see valuation upside to retain outperform," Forsyth Barr says. Ebos is down 5.5% at NZ$32.00. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

August 27, 2025 20:44 ET (00:44 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2562777296?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 08:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562777296","market":"sh","top_or_hot":-1,"title":"EBOS Loses Bull Following Soft Annual Result -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0044 GMT - Pharmacy group Ebos's disappointing FY 2025 result costs it a bull. Forsyth Barr downgrades Ebos to neutral from outperform, and cuts its price target by 19% to NZ$37.25 after making material reductions to its earnings forecasts and projecting higher capex. Analyst Matt Montgomerie says the drivers of Ebos's softer-than-expected result and outlook commentary don't appear to be structural. Forsyth Barr still sees Ebos as positioned for medium-term growth. \"But at 23x our revised 12-month forward EPS with a high single-digit three-year forward EPS compound annual growth rate, we don't see valuation upside to retain outperform,\" Forsyth Barr says. Ebos is down 5.5% at NZ$32.00. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 27, 2025 20:44 ET (00:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EBOS Loses Bull Following Soft Annual Result -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEBOS Loses Bull Following Soft Annual Result -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-28 08:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0044 GMT - Pharmacy group Ebos's disappointing FY 2025 result costs it a bull. Forsyth Barr downgrades Ebos to neutral from outperform, and cuts its price target by 19% to NZ$37.25 after making material reductions to its earnings forecasts and projecting higher capex. Analyst Matt Montgomerie says the drivers of Ebos's softer-than-expected result and outlook commentary don't appear to be structural. Forsyth Barr still sees Ebos as positioned for medium-term growth. \"But at 23x our revised 12-month forward EPS with a high single-digit three-year forward EPS compound annual growth rate, we don't see valuation upside to retain outperform,\" Forsyth Barr says. Ebos is down 5.5% at NZ$32.00. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 27, 2025 20:44 ET (00:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7103","symbol_name":"保健护理产品经销商","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2562777296","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562777296","pubTimestamp":1756341840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0044 GMT - Pharmacy group Ebos's disappointing FY 2025 result costs it a bull. Forsyth Barr downgrades Ebos to neutral from outperform, and cuts its price target by 19% to NZ$37.25 after making material reductions to its earnings forecasts and projecting higher capex. Analyst Matt Montgomerie says the drivers of Ebos's softer-than-expected result and outlook commentary don't appear to be structural. Forsyth Barr still sees Ebos as positioned for medium-term growth. \"But at 23x our revised 12-month forward EPS with a high single-digit three-year forward EPS compound annual growth rate, we don't see valuation upside to retain outperform,\" Forsyth Barr says. Ebos is down 5.5% at NZ$32.00. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7103":"保健护理产品经销商","EBO.AU":"EBOS GROUP LIMITED","BK8046":"保健护理产品经销商","EBO.NZ":"Ebos Group Limited Ordinary Shares"},"translate_title":"EBOS因年度业绩疲软而失去牛市——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBO.AU":0.9,"EBO.NZ":0.9},"content_text":"0044 GMT - Pharmacy group Ebos's disappointing FY 2025 result costs it a bull. Forsyth Barr downgrades Ebos to neutral from outperform, and cuts its price target by 19% to NZ$37.25 after making material reductions to its earnings forecasts and projecting higher capex. Analyst Matt Montgomerie says the drivers of Ebos's softer-than-expected result and outlook commentary don't appear to be structural. Forsyth Barr still sees Ebos as positioned for medium-term growth. \"But at 23x our revised 12-month forward EPS with a high single-digit three-year forward EPS compound annual growth rate, we don't see valuation upside to retain outperform,\" Forsyth Barr says. Ebos is down 5.5% at NZ$32.00. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 27, 2025 20:44 ET (00:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}